Intrexon completes acquisition of MediStem

Monday, March 10, 2014

Intrexon, a provider of synthetic biology, has completed the acquisition of San Diego-based Medistem, a pioneer in the development of Endometrial Regenerative Cells (ERCs), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon’s existing suite of synthetic biology technologies.

[Read More]

Medistem collaborates with Boston academic researcher

Wednesday, July 31, 2013

Medistem, developer of Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product, will collaborate with Reza Abdi, M.D., transplant nephrologist at Brigham and Women’s Hospital and assistant professor of medicine, Harvard Medical School. The company will provide Abdi with its ERCs and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for type 1 diabetes. The company has FDA clearance to initiate a dose-escalating phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.

[Read More]